<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01686542</url>
  </required_header>
  <id_info>
    <org_study_id>SWAN-cpAF</org_study_id>
    <nct_id>NCT01686542</nct_id>
  </id_info>
  <brief_title>CPVI Plus Renal Sympathetic Modification Versus CPVI Alone for AF（Atrial Fibrillation） Ablation</brief_title>
  <official_title>Circumferential Pulmonary Vein Isolation (CPVI) Plus Renal Sympathetic Modification Versus CPVI Alone for AF Ablation: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Second Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Second Affiliated Hospital of Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a randomized control trial. The purpose of this study is to observe&#xD;
      the efficacy and safety of atrial fibrillation ablation, comparing circumferential pulmonary&#xD;
      vein isolation (CPVI) plus renal sympathetic modification (RSM) with CPVI alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Basic studies suggested that sympathetic nerves over-activity played an important role in the&#xD;
      pathophysiological changes of arrhythmia occurrence. Present studies of renal ablation show a&#xD;
      new method to decrease sympathetic nerves activity. Circumferential pulmonary vein isolation&#xD;
      (CPVI) is an accepted ablation method for atrial fibrillation. The investigators plan to&#xD;
      evaluate the efficiency and safety of CPVI plus renal sympathetic modification for atrial&#xD;
      fibrillation ablation comparing with CPVI alone. The trial is going to recruit 100 patients&#xD;
      randomized into two groups (CPVI+RSM group VS CPVI group = 50:50) with a follow-up duration&#xD;
      of 4 years. The investigators aim to observe the relapse of atrial tachyarrhythmia lasting&#xD;
      more than 30 seconds, the incidence of composite cardiovascular events after renal&#xD;
      sympathetic modification, and safety and efficacy of the intervention, comparing with CPVI&#xD;
      alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 2012</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The relapse rate of atrial tachyarrhythmia</measure>
    <time_frame>Four years</time_frame>
    <description>Atrial tachyarrhythmia lasting more than 30 seconds consider relapsed</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>CPVI+RSM group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Circumferential pulmonary vein isolation (CPVI) plus renal sympathetic modification for atrial fibrillation ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPVI group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Circumferential pulmonary vein isolation is done alone for atrial fibrillation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CPVI plus renal sympathetic modification</intervention_name>
    <description>CPVI plus renal denervation to reduce atrial arrhythmia recurrence.</description>
    <arm_group_label>CPVI+RSM group</arm_group_label>
    <other_name>Circumferential pulmonary vein isolation (CPVI)</other_name>
    <other_name>renal denervation</other_name>
    <other_name>renal ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CPVI</intervention_name>
    <description>CPVI alone to reduce atrial arrhythmia recurrence.</description>
    <arm_group_label>CPVI group</arm_group_label>
    <other_name>circumferential pulmonary vein ablation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • ≥ 18 years old, and ≤ 75 years old of age&#xD;
&#xD;
               -  more than half a year history of atrial fibrillation, no matter paroxysmal or&#xD;
                  persistent, with clinical symptom or ECG proved&#xD;
&#xD;
               -  be ineffective to at least one kind of anti-arrhythmic drugs treatment&#xD;
&#xD;
               -  echocardiography has done to except structural heart diseases such as congenital,&#xD;
                  valvular heart diseases and kinds of cardiomyopathy&#xD;
&#xD;
               -  estimated glomerular filtration rate (eGFR) of ≥ 45ml/min&#xD;
&#xD;
               -  is competent and willing to provide written, informed consent to participate in&#xD;
                  this clinical study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • transesophageal echocardiography found thrombus in left atrial appendage&#xD;
&#xD;
               -  past history of atrial fibrillation surgical maze procedure&#xD;
&#xD;
               -  estimated glomerular filtration rate (eGFR) of &lt; 45mL/min&#xD;
&#xD;
               -  has the history of renal restenosis or renal stents implantation&#xD;
&#xD;
               -  has experienced AMI（acute myocardial infarction） (old myocardial infarction is&#xD;
                  not excluded), unstable angina pectoris, cerebrovascular accidents, and&#xD;
                  alimentary tract hemorrhage within 3 months&#xD;
&#xD;
               -  patients with sick sinus syndrome&#xD;
&#xD;
               -  pregnant women&#xD;
&#xD;
               -  mental disorders&#xD;
&#xD;
               -  patients that have allergy to contrast agent&#xD;
&#xD;
               -  patients that do not go with follow-up&#xD;
&#xD;
               -  others such as researcher considers it is not appropriate to be included into the&#xD;
                  study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuehui Yin, MD</last_name>
    <phone>0086-13508335502</phone>
    <email>yinyh63@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>2ndChongqingMU</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuehui Yin, MD</last_name>
      <phone>0086-23-63693766</phone>
      <email>yinyh63@163.com</email>
    </contact>
    <investigator>
      <last_name>Yuehui Yin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 13, 2012</study_first_submitted>
  <study_first_submitted_qc>September 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2012</study_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Second Affiliated Hospital of Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Yuehui Yin</investigator_full_name>
    <investigator_title>Director and Professor, Dept. of Cardiology, the second affiliated hospital of Chongqing Medical University, Chongqing Cardiac arrhythmias service center</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

